Clinical Trials
30 results.
LONDON (May 29, 2024) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce funding for…
LONDON (April 3, 2024) — Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may…
LONDON (Feb. 23, 2024) — Cure Parkinson’s and Van Andel Institute are delighted to announce funding for a Phase 2 clinical trial…
A “blockbuster” weight loss medication hailed as the “2023 Breakthrough of the Year” by Science also may have game-changing implications for Parkinson’s…
Copenhagen, Denmark (August 28, 2023) — A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate…
Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…
London, United Kingdom (Jan. 10, 2023) — Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol,…
GRAND RAPIDS, Mich. (Nov. 1, 2022) — A pair of cancer medications that act as a one-two punch against malignant cells demonstrated increased survival in…